Share Name Share Symbol Market Type Share ISIN Share Description
Summit Therapeutics Plc LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 20.50 18.00 23.00 0.00 0.00 0.00 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 43.1 5.0 9.2 2.2 69

Summit Therapeutics plc Notification Of Transactions Of Persons Discharging Managerial Responsibilities

15/01/2020 12:15pm

UK Regulatory (RNS & others)


 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ("Summit Therapeutics" or the "Company") 
 
   Notification of Transactions of Persons Discharging Managerial 
Responsibilities 
 
   Oxford, UK, and Cambridge, MA, US, 15 January 2020 - Summit Therapeutics 
(AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces 
that it has received notification that on 14 January 2020, Mr Robert W. 
Duggan, a Non-Executive Director of the Company, sold a total of 
33,321,870 ordinary shares and transferred a total of 4,998,279 warrants 
to various trusts as detailed below. 
 
 
 
 
                    Number of Ordinary    Sale Price per    Number of Warrants 
Name of Trust          Shares Sold       Ordinary Share*       Transferred 
------------------  ------------------  ------------------  ------------------ 
Daniel Douglas 
 Duggan Trust                1,753,780          22.1 pence             263,067 
------------------  ------------------  ------------------  ------------------ 
Dante Eon Duggan 
 Trust                       1,753,780          22.1 pence             263,067 
------------------  ------------------  ------------------  ------------------ 
David Michael 
 Duggan Trust                1,753,780          22.1 pence             263,067 
------------------  ------------------  ------------------  ------------------ 
Diamond Augustus 
 Duggan Trust                1,753,780          22.1 pence             263,067 
------------------  ------------------  ------------------  ------------------ 
Diana Star Duggan 
 Trust                       1,753,780          22.1 pence             263,067 
------------------  ------------------  ------------------  ------------------ 
Dsara Ann Duggan 
 Trust                       1,753,780          22.1 pence             263,067 
------------------  ------------------  ------------------  ------------------ 
Dylan Duke Duggan 
 Trust                       1,753,780          22.1 pence             263,067 
------------------  ------------------  ------------------  ------------------ 
Mahkam Zanganeh 
 Revocable Trust            10,522,705          22.1 pence           1,578,405 
------------------  ------------------  ------------------  ------------------ 
Shaun Zanganeh 
 Irrevocable 
 Trust                      10,522,705          22.1 pence           1,578,405 
------------------  ------------------  ------------------  ------------------ 
Total                       33,321,870                               4,998,279 
------------------  ------------------  ------------------  ------------------ 
 
 
   * The sale price per ordinary share has been converted from US Dollars 
at an exchange rate of $1.2900 to GBP1.00. 
 
   Following the completion of these dealings, Mr Duggan has the following 
interest in the Company's ordinary shares and warrants, respectively: 
 
 
 
 
                                                     % of Issued 
                                     Shareholding   Share Capital    Warrants 
-----------------  ----------------  ------------  ---------------  ---------- 
                   Non-Executive 
Robert W. Duggan    Director          211,123,385           62.85%  19,925,276 
-----------------  ----------------  ------------  ---------------  ---------- 
 
 
   This announcement contains inside information for the purposes of 
Article 7 of EU Regulation 596/2014. The person responsible for 
arranging for the release of this announcement on behalf of the Company 
is Richard Pye, Vice President, Investor Relations and Corporate 
Affairs. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics to 
treat infections caused by C. difficile, N. gonorrhoeae and 
Enterobacteriaceae and are using our proprietary Discuva Platform to 
expand our pipeline. For more information, visit www.summitplc.com and 
follow us on Twitter @summitplc. 
 
   For more information, please contact: 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)             Tel:               44 (0)1235 443 951 
Michelle Avery (US office)                                               +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated Adviser)   Tel:              +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson / Ludovico 
Lazzaretti 
 
N+1 Singer (Joint Broker)                          Tel:              +44 (0)20 7496 3000 
Aubrey Powell / George Tzimas, Corporate Finance 
 Tom Salvesen, Corporate Broking 
 
Bryan Garnier & Co Limited (Joint Broker)          Tel:              +44 (0)20 7332 2500 
Phil Walker / Dominic Wilson 
 
MSL Group (US)                                     Tel:                  +1 781 684 6552 
                                                              mailto:summit@mslgroup.com 
Erin Anthoine                                                        summit@mslgroup.com 
                                                          ------------------------------ 
 
Consilium Strategic Communications (UK)            Tel:              +44 (0)20 3709 5700 
Mary-Jane Elliott / Sue Stuart /                          mailto:summit@consilium-comms. 
 Sukaina Virji / Lindsey Neville                          com 
                                                          summit@consilium-comms.com 
                                                          ------------------------------ 
 
 
   The information set out below is provided in accordance with the 
requirements of Article 19(3) of the Market Abuse Regulation (EU) No 
596/2014. 
 
 
 
 
1   Details of the persons discharging managerial responsibilities/person 
     closely associated 
    ----------------------------------------------------------------------------- 
a)  Name                            (i) Robert W. Duggan 
    -----------------------  ---------------------------------------------------- 
2   Reason for the notification 
    ----------------------------------------------------------------------------- 
a)  Position / status               (i) Non-Executive Director 
    -----------------------  ---------------------------------------------------- 
b)  Initial notification /   Initial notification 
    Amendment 
    -----------------------  ---------------------------------------------------- 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
    ----------------------------------------------------------------------------- 
a)  Name                     Summit Therapeutics plc 
    -----------------------  ---------------------------------------------------- 
b)  LEI                      213800NRW8AOMYMTBD89 
    -----------------------  ---------------------------------------------------- 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
    ----------------------------------------------------------------------------- 
a)  Description of the       Ordinary shares of 1 penny each 
    financial instrument, 
    type of instrument 
 
 
    Identification code      GB00BN40HZ01 
    -----------------------  ---------------------------------------------------- 
b)  Nature of the            Sale of ordinary shares of one penny nominal value 
    transactions 
    -----------------------  ---------------------------------------------------- 
c)  Price(s) and volume(s)     Price(s)                     Volume(s) 
    -----------------------    ---------------------------  ------------------- 
                               (i) 22.1p (exercise price)      (i) 33,321,870 
    -----------------------    ---------------------------  ------------------- 
 
d)  Aggregated information 
     - Aggregated volume       33,321,870 ordinary shares 
     - Price                   22.1 pence 
    -----------------------  ---------------------------------------------------- 
e)  Date of the              14 January 2020 
    transactions 
    -----------------------  ---------------------------------------------------- 
f)  Place of the             Outside a trading venue 
    transactions 
    -----------------------  ---------------------------------------------------- 
 
 
 
 
 
 
1   Details of the persons discharging managerial responsibilities/person 
     closely associated 
    -------------------------------------------------------------------------------------- 
a)  Name                              (ii) Robert W. Duggan 
    -------------------------  ----------------------------------------------------------- 
2   Reason for the notification 
    -------------------------------------------------------------------------------------- 
a)  Position / status                 (ii) Non-Executive Director 
    -------------------------  ----------------------------------------------------------- 
b)  Initial notification /     Initial notification 
    Amendment 
    -------------------------  ----------------------------------------------------------- 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
    -------------------------------------------------------------------------------------- 
a)  Name                       Summit Therapeutics plc 
    -------------------------  ----------------------------------------------------------- 
b)  LEI                        213800NRW8AOMYMTBD89 
    -------------------------  ----------------------------------------------------------- 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
    -------------------------------------------------------------------------------------- 
a)  Description of the         Ordinary shares of 1 penny each 
    financial instrument, 
    type of instrument 
 
 
    Identification code        GB00BN40HZ01 
    -------------------------  ----------------------------------------------------------- 
b)  Nature of the              Transfer of warrants to subscribe for ordinary shares 
    transactions                of one penny nominal value 
    -------------------------  ----------------------------------------------------------- 
c)  Price(s) and volume(s)       Price(s)                Volume(s) 
    -------------------------    ----------------------  ------------------------------- 
                                 (i) n/a                    (ii) 4,998,279 
    -------------------------    ----------------------  ------------------------------- 
 
d)  Aggregated information 
     - Aggregated volume         4,998,279 warrants to subscribe for ordinary shares 
     - Price                     n/a 
    -------------------------  ----------------------------------------------------------- 
e)  Date of the transactions   14 January 2020 
    -------------------------  ----------------------------------------------------------- 
f)  Place of the transactions  Outside a trading venue 
    -------------------------  ----------------------------------------------------------- 
 
 
   -END- 
 
 
 
 
 
 

(END) Dow Jones Newswires

January 15, 2020 07:15 ET (12:15 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

1 Year Summit Therapeutics Chart

1 Year Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

1 Month Summit Therapeutics Chart
Your Recent History
LSE
SUMM
Summit The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200226 23:46:36